The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.7M data for 1.2M Compounds and 9.0K Targets. Of those, 1,244K data for 572K Compounds and 4.4K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

67 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
II. Discovery of a novel series of CXCR3 antagonists with a beta amino acid core.EBI
Sanofi
I. Discovery of a novel series of CXCR3 antagonists. Multiparametric optimization of N,N-disubstituted benzylamines.EBI
Sanofi
SAR156497, an exquisitely selective inhibitor of aurora kinases.EBI
Sanofi
Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kß inhibitors.EBI
Sanofi
Discovery and optimization of pyrimidone indoline amide PI3Kß inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers.EBI
Sanofi
Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.EBI
Sanofi
Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic.EBI
Sanofi
Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kß inhibitors.EBI
Sanofi
Discovery of N-substituted 7-azaindoles as Pan-PIM kinases inhibitors - Lead optimization - Part III.EBI
Sanofi
Development of a novel NURR1/NOT agonist from hit to lead and candidate for the potential treatment of Parkinson's disease.EBI
Sanofi
Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3EBI
Sanofi
The use of virtual screening and differential scanning fluorimetry for the rapid identification of fragments active against MEK1.EBI
Sanofi